Low cholesterol levels are good markers for central hypothyroidism in case with dialysis using roxadustat
Key Clinical Message Recently, hypoxia‐inducible factor prolyl hydroxylase (HIF‐PH) inhibitors have been used for renal anemia, but side effects have also been reported. We report on the association of central hypothyroidism and cholesterol with roxadustat. Based on this case and previous reports, w...
Saved in:
| Main Authors: | Serina Kita, Hiroshi Okuyama, Takaya Kondo, Mizuki Hayashi, Shinichiro Nakao, Toshitaka Sawamura, Keiji Fujimoto, Atsushi Nakagawa, Hitoshi Yokoyama, Kengo Furuichi |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-09-01
|
| Series: | Clinical Case Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ccr3.9400 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A Case Report of Hypothyrotropin Hypothyroidism Caused by Roxadustat
by: YAN Xuelian, et al.
Published: (2025-03-01) -
Issues on clinical application of hypoxia-inducible factor prolyl hydroxylase inhibitor Roxadustat
by: TU Yan, et al.
Published: (2020-01-01) -
Roxadustat has risks of reversible central hypothyroidism in patients undergoing hemodialysis: a single-center retrospective cohort study
by: Emiko Otsuka, et al.
Published: (2024-12-01) -
Roxadustat in CKD and transplant patients: A new era in anemia management
by: Muhammad Tassaduq Khan, et al.
Published: (2025-03-01) -
Study on HIF-PHI combined with iron supplement in treatment of renal anemia in rats
by: Zhaoli Gao, et al.
Published: (2025-03-01)